NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors ...
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...
Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.
PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.
Zacks.com on MSN5d
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & MoreNovartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of inv ...
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback